News
Stay up to date on the latest company news:
16 September 2026
Abalos Therapeutics Publishes Two Articles in Viruses Further Validating its AdaptInnate Approach to Treat Solid Tumors
4 November 2025
Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025
23 October 2025
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
14 October 2025
Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001's Potential to Overcome Cancer Immunotherapy Hurdles
09 October 2024
Abalos Therapeutics Appoints Gerben Moolhuizen as Chief Executive Officer
18 March 2024
Abalos selected for funding project by KMU-innovativ, an initiative from Germany‘s Federal Ministry of Education and Research (BMBF)
18 October 2022
Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer
12 August 2022
Abalos Therapeutics---arenaviruses take on cancer
14 October 2021
Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million
05 February 2020
Abalos Therapeutics Expands Leadership Team with Drug Development and Viral Therapy Manufacturing Experts
15 October 2019
Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
Events
Want to get in touch with the Abalos Therapeutics Team? Meet us at the following events:
September 15-18, 2026
55th Annual Meeting of the German Society of Immunology (DGfI)
Location: Munich, Germany
Participant: Karl Sebastian Lang, Scientific Founder of Abalos, Chair of Immunology at the Medical Faculty, University Duisburg-Essen
September 23-25, 2026
19th International Symposium on Translational Research in Oncology
Location: Dublin, Ireland
Participant: Thomas Bogenrieder, Chief Medical Officer (CMO)
October 23-27, 2026
ESMO Congress 2026
Location: Madrid, Spain
Participants: Thomas Bogenrieder, CMO / Gerben Moolhuizen, CEO